Efficacy of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Efficacy of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma - Efficacy of Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042750

Enrollment

300

Registered

2020-12-21

Start date

2020-12-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1The diagnosis confirmed by histologic or cytologic analysis or clinical features. 2Diagnosed unresectable HCC.3More over 4week past since resection,RFA or TACE.4Child-Pugh score within 6point.5Performance status by ECOG 0~1.6Screening performed HB virus and HC virus.7Reserved Organ functionWBC:2,000/mm3,10,000/mm3Platelet:50,000/mm3 Hemoglobin:8.0 g/dlTotal Bilirubin:2.0 mg/dlPT:70%Creatinine:2 mg/dlAlbumin:2.8 g/dl 8All patients gave written informed consent.

Exclusion criteria

Exclusion criteria: 1Untreated or incompletely treated esophageal or gastric varices.2With bleeding or high risk of bleeding.3Thromboembolic event.4Wounded.5Brain metastasis.6Uncontrolled Hypertension. 7Uncontrolled Ascites. 8History of autoimmune disease. 9Pulmonary fibrosis. 10Tuberculosis. 11Severe Hart failure. 12Long QT Syndrome. 13infection within 4weeks. 14Vaccination within 4weeks. 15Pregnant. 16Allergic. 17Un suitable Patient.

Design outcomes

Primary

Measure	Time frame
OS,PFS and TE(within3month by enhanced CT or enhanced MRI) based on RECIST1.1	—

Secondary

Measure	Time frame
safety:HFS,diarrhea,malaise,appitite loss,liver failuar,proteinuria,Tumor marker(AFP,DCP),Child-Pugh score	—

Countries

Japan

Contacts

Public ContactKoji Takai

Gifu university school of medicine First Dept of internal medicine

koz@gifu-u.ac.jp0582306308

Outcome results